Understanding retatrutide patient eligibility starts with one of the most foundational metrics in obesity medicine: body mass index. In the Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.; NCT04881760), researchers enrolled adults with a BMI of ≥30 kg/m² (up to a maximum of 50 kg/m²) or a BMI of ≥27 kg/m² if the participant had at least one weight-related comorbidity, such as hypertension or dyslipidemia. This two-tiered threshold mirrors the eligibility structure used in other major anti-obesity medication trials and reflects current clinical thinking about where the cardiometabolic risk of excess weight becomes medically actionable.
For patients who fall in the 27–29.9 BMI range, the presence of a qualifying comorbidity is not a technicality — it is a meaningful clinical signal that excess weight is already affecting health. Conditions such as elevated blood pressure, abnormal lipid levels, obstructive sleep apnea, and certain metabolic disorders have historically been recognized as sufficient justification for pharmacologic intervention even at a lower BMI threshold.
It is worth noting that all participants in the Phase 2 trial received diet and physical activity counseling as background therapy throughout the 48-week treatment period. Medication alone was not the intervention — structured lifestyle support was built into the protocol from the start. Any future clinical use of retatrutide would likely reflect that same philosophy.
Beyond BMI, the Phase 2 protocol defined a detailed set of inclusion and exclusion criteria that shaped who could safely participate. Reviewing these criteria gives prospective patients a clearer picture of who qualifies for retatrutide based on available evidence.
The exclusion of prior bariatric surgery (beyond liposuction) and recent significant weight changes reflects the researchers' goal of studying a well-defined population with stable baseline characteristics. These criteria help ensure that any observed weight loss could be attributed to the drug itself rather than confounding variables.
The cardiometabolic benefits observed in the trial were substantial. At 24 weeks, the 12mg dose group showed a 34.0% reduction in fasting triglycerides and a 17.3% reduction in total cholesterol compared to a modest 3.1% and 2.2% reduction in the placebo group, respectively. LDL cholesterol fell by approximately 15.6–16.9% in the 8mg group at the same timepoint. These findings suggest that the retatrutide BMI requirements are not merely administrative — the drug appears to confer meaningful metabolic benefits for those who meet them.
This is one of the most common questions raised about retatrutide exclusion criteria. In the Phase 2 obesity trial, participants with type 2 diabetes — defined by an HbA1c of 6.5% or higher, a fasting glucose of 126 mg/dL or higher, or a random glucose reading of 200 mg/dL or higher — were explicitly excluded. The trial was designed to study retatrutide's effect on obesity in people without established type 2 diabetes.
This does not mean retatrutide has no relevance for people with diabetes. Separate Phase 3 trials are evaluating retatrutide in populations with type 2 diabetes. However, based on the obesity-focused trial data available through April 2026, the published efficacy and safety profile for obesity treatment applies specifically to adults without type 2 diabetes. Patients with prediabetes or impaired fasting glucose who did not meet the formal diabetes threshold may have been eligible, though individual screening results would have determined this on a case-by-case basis.
Based on the Phase 2 protocol, prior use of any GLP-1 receptor agonist was an exclusion criterion. This is a clinically significant point for the large and growing population of patients who have already tried semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) — medications that have become widely used in obesity treatment over the past several years.
The rationale for this exclusion in the research setting was methodological: enrolling participants who had previously responded to, or failed, a GLP-1 agonist would introduce confounding variables that complicate interpretation of results. Whether this exclusion will carry forward into clinical practice guidelines once retatrutide receives regulatory review remains to be seen. The Phase 3 TRIUMPH-4 trial, which reported a remarkable 28.7% mean weight loss at the 12mg dose over 68 weeks — the highest ever recorded in a Phase 3 obesity trial — has not publicly specified whether prior GLP-1RA use was an exclusion criterion in its design.
For context, the following table compares retatrutide's Phase 3 weight loss outcome against benchmark Phase 3 results from the two most prominent approved anti-obesity medications:
| Medication | Trial | Duration | Mean Weight Loss (Top Dose) |
|---|---|---|---|
| Semaglutide 2.4mg | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12mg | TRIUMPH-4 (Phase 3) | 68 weeks | 28.7% |
Retatrutide — commonly referred to as reta in patient communities, and sometimes called a "triple G" for its triple agonist mechanism targeting GLP-1, GIP, and glucagon receptors simultaneously — represents a mechanistically distinct approach from semaglutide and tirzepatide. The addition of glucagon receptor agonism is thought to contribute to the drug's enhanced energy expenditure effects, which may help explain why the weight loss outcomes exceed those seen with dual or single agonists. Patients who have experienced significant "food noise" reduction on prior GLP-1 therapies but plateaued in their weight loss may be particularly interested in what a triple agonist could offer — though clinical eligibility for any future use will depend on the prescribing guidelines established at the time of potential approval.
It is important to note that as of April 2026, the peer-reviewed Phase 3 publication is still pending, and no New Drug Application has been filed with the FDA. The approval timeline has not been publicly confirmed. All efficacy data cited here reflects clinical trial conditions and may not predict individual outcomes.
For patients who believe they may meet the retatrutide comorbidities and BMI thresholds outlined above — or who simply want to stay informed as Phase 3 data continues to emerge — joining the waitlist at glp3md.com is a way to remain at the front of a rapidly evolving conversation. The waitlist is an informational resource: no promises are made regarding medication access, treatment availability, or prescriptions, as retatrutide has not received FDA approval. What glp3md.com does offer is timely, evidence-based updates grounded in peer-reviewed data — so that when the regulatory landscape does shift, informed patients are ready to have the right conversations with their own providers.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.